Dianthus Therapeutics, Inc. (NasdaqCM: DNTH)
Health Care · Biotechnology · US
$111.10
+1.45% today · +357.2% 1Y
Dianthus Therapeutics, Inc. (NasdaqCM: DNTH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.21B and employs 92 people.
Over the last twelve months the share price has gained 357.2%, trading between 22.06 and 117.88.
Tweenvest scores Dianthus Therapeutics, Inc. across four factors: quality 31/100. Its strongest factor is quality.
DNTH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.21B
- Revenue (TTM)
- $1.90M
- P/E
- —
- EPS
- -4.11
- Dividend yield
- —
- Beta (5Y)
- 0.08
- 52-week high
- $117.88
- 52-week low
- $22.06
- Avg volume (3M)
- —
- Shares outstanding
- 55.93M
- Employees
- 92
- Next earnings
- —
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- Founded
- 2019
- Listed since
- Jun 21, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.70 | +0.28% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.24 | -1.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.